News Search

Vinson & Elkins advised Lexicon Pharmaceuticals, Inc. in a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $250 million.

Vinson & Elkins advised Reata Pharmaceuticals Inc. (“Reata”), a global biopharmaceutical company committed to developing and commercializing novel therapeutics for patients with serious or life-threatening diseases, in its entry into a definitive agreement under which Biogen Inc. has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.

Vinson & Elkins advised Lexicon Pharmaceuticals, Inc. in the completion of a public offering and concurrent private placement of shares of its common stock.

Vinson & Elkins advised Lexicon Pharmaceuticals, Inc. in connection with an underwritten public offering of 16,843,600 shares of its common stock at a public offering price of $2.50 per share.

Vinson & Elkins advised Acuity Eyecare Holdings, LLC, a portfolio company of Riata Capital Group, a Dallas-based private equity investment firm, in connection with a GP-led secondary transaction.